James P. Mitchum
CIK 1597439 · last filed 2021-06-15
James P. Mitchum is a corporate insider who has filed 6 SEC Form 4 insider transactions across 2 companies since 2015. The most recent filing, for TENX, was dated Jun 15, 2021. Across all open-market trades the lifetime net is +$50.5K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $4 across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TENX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
79 T.W. ALEXANDER DRIVE
RESEARCH TRIANGLE PARK, NC 27709
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TENX | Director | 2 | $1.78 | $4 | $50.5K | 5 | 2021-06-15 |
| NephroGenex, Inc. (NRX) Delisted | Director | — | — | — | $0 | 1 | 2015-05-04 |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-15 | TENX | Grant (A) | — | $0 | EDGAR |
| 2020-05-15 | TENX | Grant (A) | — | $0 | EDGAR |
| 2019-04-18 | TENX | Grant (A) | — | $0 | EDGAR |
| 2016-11-22 | TENX | Disp (D) | +7,000 | $10.6K | EDGAR |
| 2016-02-19 | TENX | Buy (P) | +19,000 | $50.5K | EDGAR |
| 2015-05-04 | NephroGenex, Inc. (NRX) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.